Hybrid-artificial liver support system

Surgery

Volumn 131, Issue 1 SUPPL., 2002, Pages

  Yamashita, Yo Ichi ^a   Shimada, Mitsuo ^a   Ijima, Hiroyuki ^a   Nakazawa, Kohji ^a   Funatsu, Kazumori ^a   Sugimachi, Keizo ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

POLYURETHAN;

ANIMAL CELL; ARTICLE; ARTIFICIAL LIVER; ETHICS; HISTORY; HUMAN; HUMAN CELL; HYBRID; LIVER CELL; LIVER PERFUSION; NONHUMAN; PRIORITY JOURNAL; PURIFICATION; SURFACE PROPERTY;

EID: 0036166286     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1067/msy.2002.120118     Document Type: Article

References (51)

1. Acute and subacute fulminant hepatic failure; the role of liver transplantation
2. Liver transplantation for fulminant hepatic failure
3. Living related liver transplantation for fulminant hepatic failure
4. Experiences in the treatment of fulminant hepatic failure by conservative therapy, charcoal haemoperfusion, and polyacrylonitrile haemodialysis
5. Large pore hemodialysis in fulminant hepatic failure
6. Favorable effect of new artificial liver support on survival of patients with fulminant hepatic failure
7. Extracorporeal methods of liver failure treatment
8. Efficacy and limitations of plasma exchange in patients with acute hepatic failure; comparing with hemoadsorption, and with impaired regeneration syndrome
9. Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure
10. Hemodiabsorption in the treatment of acute hepatic failure
11. Evaluation of BioLogic-DT sorbent-suspension dialyser in patients with fulminant hepatic failure
12. Hepatic recovery following extracorporeal detoxification in acute on chronic hepatic failure (AoCHF) - Clinical experience
13. Immunochemical observations in clinical heterologous (xenogeneic) liver perfusions
14. Experience in the treatment of hepatic failure by intermittent liver hemoperfusions
15. Experience in treating hepatic coma by extracorporeal liver perfusion
16. Extracorporeal hemoperfusion over the baboon and human liver to treat fulminant hepatitis and its bridge role for liver transplantation
17. Clinical experience of postoperative liver failure treatment with pig or baboon liver cross-hemodialysis with an interposed membrane
18. Acute hepatic coma treated by cross-circulation or exchange transfusion
19. Hybrid bioartificial liver in hepatic failure: Preliminary clinical report
20. Temporary organ substitution by hemoperfusion through suspension of active donor hepatocytes in a total complex of intensive therapy in patients with acute hepatic insufficiency
21. The hepatix extracorporeal liver assist device: Initial clinical experience
22. Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure
23. Early clinical experience with a hybrid bioartificial liver
24. Clinical experience with bioartificial liver in the treatment of severe liver failure. A phase I clinical trial
25. High albumin production by multicellular spheroids of adult rat hepatocytes formed in pores of polyurethane form
26. Formation of spherical multicellular aggregate (spheroid) of animal cells in the pores of polyurethane foam as a cell culture substratum and its application to a hybrid artificial liver
27. Hepatocyte spheroids in polyurethane foams: Functional analysis and application for a hybrid artificial liver
28. Formation of porcine hepatocyte spherical multicelllar aggregates (spheroid) and analysis of drug metabolic functions
29. Evaluation of a hybrid artificial liver using a polyurethane foam packed-bed culture system in dogs
30. Development of hybrid artificial liver support system using spheroid culture and application to warm ischemic liver failure in dog and pig as a preclinical test
31. Modulation of immunologic reactions between cultured porcine hepatocytes and human Sera
32. The efficacy of nafamostat mesilate on the performance of a hybrid-artificial liver using a polyurethane foam/porcine hepatocytes spheroid culture system in human plasma
33. Infecfion of human cells by an endogenous retrovirus of pigs
34. Infection by porcine endogenous retrovirus after islet xenotransplantation in SCID mice
35. Transfer of porcine endogenous retrovirus across hollow fiber membranes: Significance to a bioartificial liver
36. Search for cross species transmission of porcine endogenous retrovirus in patients treated with living pig tissue
37. Evidence of absence of porcine endogenous retrovirus (PERV) infection in patients treated with a bioartificial liver support system
38. An approach to the control of disease transmission in pig-to-human xenotransplantation
39. Prevention of acute liver failure in rats with reversibly immortalized human hepatocytes
40. Treatment of surgical induced acute liver failure with transplantation of highly differentiated immortalized human hepatocytes
41. Development of a non-transformed human liver cell line with differentiated-hepatocyte and ureasynthetic functions; applicable for bioartificial liver
42. Embryonic stem cell lines derived from human blastocysts
43. Bone marrow as a potential source of hepatic oval cells
44. Purified hematopoietic stem cells can differentiate into hepatocytes in vivo
45. Heterogeneity of growth potential of adult rat hepatocytes in vitro
46. Flow-cytometric separation and enrichment of hepatic progenitor cells in the developing mouse liver
47. Reconstruction of hepatic organoid by rat small hepatocytes and hepatic nonparenchymal cells
48. Expression of vascular endothelial growth factor promotes colonization, vascularization, and growth of transplanted hepatic tissues in the mouse